In preparation for a wave of expensive gene and cell therapies, the Institute for Clinical and Economic Review is reconsidering how it determines fair prices for one-time treatments that promise long-term effects. ICER requested public input on its so-called value framework on the day that Novartis subsidiary AveXis announced it withheld manipulated data on the world’s most expensive drug, gene therapy Zolgensma, highlighting the uncertainty of the data on which prices for gene therapies are set. ICER on Tuesday (Aug...